February 13, 2024- UT Southwestern Medical Center is partnering with Pfizer Inc. to develop RNA-enhanced delivery technologies for genetic medicine therapies through the Dallas-based medical center’s Program in Genetic Drug Engineering.
This agreement will further UT Southwestern’s research and development of cell-targeted nucleic acid and gene editing therapies that Pfizer may apply to its portfolio of investigational programs.
The joint effort will bring together UTSW’s recent advances in understanding RNA-based biology and improved delivery systems for RNA-based therapies with Pfizer’s robust and extensive RNA knowledge, rapid manufacturing capabilities, and scientific innovation. It has the potential to propel the concept of genetic medicines forward into new therapeutic areas.